Kisqali in Combination with Hormonal Therapy and Ovarian Suppression Effective Treatment for Metastatic Hormone-Receptor-Positive, HER2-Negative Disease in Premenopausal Women: 2017 SABCS

The targeted therapy Kisqali (chemical name: ribociclib) is approved to be used in combination with an aromatase inhibitor to treat advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that hasn’t been treated with hormonal therapy yet in postmenopausal women. Dr. Debu Tripathy, professor of medicine and chairperson of the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center, discusses the results of the MONALEESA-7 study he presented at the 2017 San Antonio Breast Cancer Symposium showing that Kisqali can help treat premenopausal and perimenopausal women diagnosed with the same type of breast cancer. Listen to the podcast to hear Dr. Tripathy explain: why the study is important why ovarian suppression helps make the treatments more effective the side effects caused by Kisqali why he thinks this study will change practice Editor's Note: On April 4, 2019, the U.S. Food and Drug Administration (FDA) expanded the use of Ibrance so the medicine now can be used to treat men diagnosed with advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer.